Big Tech's Growing Biopharma Prominence

If activity at the recent J.P. Morgan Healthcare Conference is an indication of what is up ahead, 2024 is set to be the year of big tech in biopharma. 

Bio Bytes
• Source: Shutterstock

Company presentations are the cornerstone of the annual J.P. Morgan Healthcare Conference, but one of the most well-attended talks at this year's meeting was delivered by Kimberly Powell, vice president and general manager of health care at NVIDIA. Given that what happens at JPM is a reliable indicator of things to come, this year is set to be the year big tech takes a prominent seat at the biopharma table.

Powell made two industry-related announcements. First, she said AI-driven drug biotech Recursion Pharmaceuticals, Inc., into which NVIDIA has invested $50m, had released an API as part of NVIDIA’s BioNemo cloud service

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Intelligence

More from In Vivo

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By 

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By 

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.

Dealmaking Quarterly Statistics, Q1 2025

 
• By 

During Q1, biopharma M&A deal value reached $38.4bn and drew in $60.8bn in potential deal value from alliances. Device company M&A values reached $8.7bn.